ELVN

Enliven Therapeutics (ELVN)

About Enliven Therapeutics (ELVN)

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Details

Daily high
$48.53
Daily low
$45.52
Price at open
$45.95
52 Week High
$48.53
52 Week Low
$14.78
Market cap
2.9B
Dividend yield
0.00%
Volume
1.4M
Avg. volume
1.7M
P/E ratio
-25.89

Enliven Therapeutics News

Details

Daily high
$48.53
Daily low
$45.52
Price at open
$45.95
52 Week High
$48.53
52 Week Low
$14.78
Market cap
2.9B
Dividend yield
0.00%
Volume
1.4M
Avg. volume
1.7M
P/E ratio
-25.89